Solid Biosciences, Inc. (SLDB)
10.22
+0.50
(+5.14%)
USD |
NASDAQ |
Aug 27, 15:41
Solid Biosciences Enterprise Value : 663.66M for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 663.66M |
| August 25, 2026 | 681.53M |
| August 24, 2026 | 604.79M |
| August 21, 2026 | 619.51M |
| August 20, 2026 | 598.48M |
| August 19, 2026 | 665.76M |
| August 18, 2026 | 596.38M |
| August 17, 2026 | 598.48M |
| August 14, 2026 | 608.99M |
| August 13, 2026 | 596.38M |
| August 12, 2026 | 594.80M |
| August 11, 2026 | 572.20M |
| August 10, 2026 | 541.71M |
| August 07, 2026 | 523.84M |
| August 06, 2026 | 557.48M |
| August 05, 2026 | 559.58M |
| August 04, 2026 | 548.02M |
| August 03, 2026 | 484.94M |
| July 31, 2026 | 489.15M |
| July 30, 2026 | 534.35M |
| July 29, 2026 | 487.05M |
| July 28, 2026 | 479.69M |
| July 27, 2026 | 471.28M |
| July 24, 2026 | 464.97M |
| July 23, 2026 | 480.74M |
| Date | Value |
|---|---|
| July 22, 2026 | 493.35M |
| July 21, 2026 | 531.20M |
| July 20, 2026 | 530.15M |
| July 17, 2026 | 558.53M |
| July 16, 2026 | 593.22M |
| July 15, 2026 | 653.15M |
| July 14, 2026 | 654.20M |
| July 13, 2026 | 663.66M |
| July 10, 2026 | 737.25M |
| July 09, 2026 | 812.94M |
| July 08, 2026 | 798.22M |
| July 07, 2026 | 813.99M |
| July 06, 2026 | 805.58M |
| July 02, 2026 | 781.40M |
| July 01, 2026 | 714.12M |
| June 30, 2026 | 692.04M |
| June 29, 2026 | 571.15M |
| June 26, 2026 | 553.43M |
| June 25, 2026 | 511.12M |
| June 24, 2026 | 549.50M |
| June 23, 2026 | 504.24M |
| June 22, 2026 | 456.02M |
| June 18, 2026 | 458.98M |
| June 17, 2026 | 358.61M |
| June 16, 2026 | 335.00M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 616.24M |
| Amgen, Inc. | 281.36B |
| Anika Therapeutics, Inc. | 276.98M |
| BioCryst Pharmaceuticals, Inc. | 2.993B |
| Imunon, Inc. | 8.586M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -54.80M |
| Total Expenses (Quarterly) | 54.80M |
| EPS Diluted (Quarterly) | -0.3814 |
| Earnings Yield | -18.67% |
| Normalized Earnings Yield | -18.28 |